Emcure Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Emcure Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹137Over the last 3 years, every ₹100 of reported profit came with ₹137 of operating cash.
Higher than 65% of Healthcare companies in India.
Self-Funding Ratio
2.3×Over the last 3 years its own operating cash covered its investment spending (capex) 2.3 times.
Higher than 72% of Healthcare companies in India.
Cash Locked Ratio
₹25For every ₹100 of sales, ₹25 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹27 tied up three years earlier.
More money tied up than 54% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹12Sales grew 54% in 3 years; of every extra ₹100 of sales, ₹12 became extra profit.
Lower than 63% of Healthcare companies in India.
Asset Productivity Ratio
+54% / +44%In 3 years sales changed by +54% while total assets changed by +44%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
1.0×Debt due within a year is covered 1.0 times by its yearly operating cash.
Lower than 51% of Healthcare companies in India.
Cash Cushion Ratio
−4%Debt, after subtracting cash, equals 4% of its market value (net debt).
Lower than 63% of Healthcare companies in India.
Tangible Assets Ratio
89%Of every ₹100 the company owns, ₹89 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 74% of Healthcare companies in India.
Tangible Net Worth Ratio
78%Of every ₹100 of net worth, ₹78 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 76% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Emcure Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns. Net profit rose 36% in the year to Mar 2026, and grew 20% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
33.4Investors pay ₹33.4 for every ₹1 of Emcure Pharmaceuticals Limited's yearly profit, lower than 57% of Healthcare companies in India.
P/B ratio
6.83The share price is 6.83 times Emcure Pharmaceuticals Limited's book value per share, higher than 72% of Healthcare companies in India.
Market cap
₹33,818 CrThe total market value of all of Emcure Pharmaceuticals Limited's shares at today's price (share price × number of shares), larger than 84% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹4,950 CrWhat Emcure Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹260.93Net worth divided by the number of shares. The share price of ₹1,783 is 6.8 times this, which is the P/B above.
Return on equity (ROE)
20.4%Emcure Pharmaceuticals Limited earned 20.4% on its shareholders' money over the last year, higher than 81% of Healthcare companies in India.
Owes vs Owns
0.48×Emcure Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns (low), higher than 80% of Healthcare companies in India.
Dividend yield
0.20%Emcure Pharmaceuticals Limited pays 0.20% of its share price as dividends a year, lower than 71% of dividend-paying Healthcare companies in India.
Revenue growth
+17%Revenue rose 17% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Profit growth
+36%Net profit rose 36% in the year to Mar 2026, and grew 20% a year on average over 3 years.
Profit margin
10.1%Emcure Pharmaceuticals Limited keeps ₹10 of every ₹100 of revenue as net profit.
Cash quality
1.02×Cash from Emcure Pharmaceuticals Limited's business was 1.02× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
11.1×Emcure Pharmaceuticals Limited's operating profit covered its interest costs 11.1 times in the year to Mar 2026.
Cash vs debt
Net debtEmcure Pharmaceuticals Limited had ₹1,418 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Emcure Pharmaceuticals Limited's P/E ratio?
Investors pay ₹33.4 for every ₹1 of Emcure Pharmaceuticals Limited's yearly profit, lower than 57% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Emcure Pharmaceuticals Limited: ₹33,818 Cr ÷ ₹4,950 Cr (31 Mar 2026) = 6.8.
What is Emcure Pharmaceuticals Limited's return on equity?
Emcure Pharmaceuticals Limited earned 20.4% on its shareholders' money over the last year, higher than 81% of Healthcare companies in India.
How much does Emcure Pharmaceuticals Limited owe compared with what it owns?
Emcure Pharmaceuticals Limited owes ₹0.48 for every ₹1 it owns (low), higher than 80% of Healthcare companies in India.
Does Emcure Pharmaceuticals Limited pay a dividend?
Yes. Emcure Pharmaceuticals Limited pays 0.20% of its share price as dividends a year, lower than 71% of dividend-paying Healthcare companies in India.
Is Emcure Pharmaceuticals Limited's revenue growing?
Revenue rose 17% in the year to Mar 2026, and grew 15% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.